Clearstead Advisors’s TG Therapeutics TGTX Stock Holding History

Clearstead Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.64K	Buy	+48	New	+$1.96K	﹤0.01%	2381
2026 Q1	–	Sell	-137	Closed	-$4.08K	–	2805
2025 Q4	$4.08K	Buy	137 +1	+0.7%	+$33	﹤0.01%	2052
2025 Q3	$4.91K	Sell	136 -66	-33%	-$2.17K	﹤0.01%	2164
2025 Q2	$7.27K	Buy	202 +136	+206%	+$5.06K	﹤0.01%	1993
2025 Q1	$2.6K	Hold	66	–	–	﹤0.01%	1850
2024 Q4	$1.99K	Buy	+66	New	+$1.89K	﹤0.01%	1843

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Clearstead Advisors's TGTX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 48 shares worth $2.64K. The stake represents ﹤0.01% of the portfolio and ranks #2381 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in TGTX as recently as Q4 2025.

Clearstead Advisors first reported a position in TGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.27K in Q2 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Clearstead Advisors held 48 shares of TG Therapeutics worth $2.64K as of Q2 2026.
TG Therapeutics was a new Clearstead Advisors position in Q2 2026.
TG Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2381 holding.
Clearstead Advisors first reported a position in TG Therapeutics in Q4 2024 and has held it in 6 quarters since.
Clearstead Advisors's TG Therapeutics position peaked at $7.27K in Q2 2025.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.